JV-1-52

JV-1-52 is a **synthetic peptide analog** functioning as a non-selective antagonist of both vasoactive intestinal peptide (VIP) receptors (VPAC1 and VPAC2) and growth hormone-releasing hormone (GHRH) receptors. It was rationally designed by modifying earlier GHRH antagonists to reduce GHRH receptor affinity while retaining or enhancing VIP receptor antagonism. JV-1-52 has demonstrated efficacy in preclinical models, including inhibition of proliferation and tumor growth in androgen-independent prostate cancer xenografts, where its mechanism includes blockade of mitogenic signalling via both VIP and GHRH pathways. Its main research utility has been in cancer biology and signaling studies[1][3].